UGT2B17 and B-cell chronic lymphocytic leukemia: Upregulated UGT2B17 expression represents an independent adverse prognostic marker associated with shorter treatment‐free survival (TFS) and shorter overall survival (OS) of CLL patients, as well as poor drug response.21, 22, 23, 24